| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/28/2008 | US20080050432 Combined Pharmaceutical Formulation with Controlled-Release Comprising Dihydropyridine Calcium Channel Blockers and HMG-COA Reductase Inhibitors |
| 02/28/2008 | US20080050431 Sustained release formulations of oxymorphone |
| 02/28/2008 | US20080050430 Pharmaceutical compositions and methods for improved bacterial eradication |
| 02/28/2008 | US20080050429 Low flush niacin formulation |
| 02/28/2008 | US20080050428 Oral Pharmaceutical Preparation Comprising a Proton Pump Antagonist and a Basic Excipient |
| 02/28/2008 | US20080050427 Analgesic combination of tramadol and meloxicam |
| 02/28/2008 | US20080050425 Combination Chemotherapy Comprising 5-Fluorouracil or a Derivative Thereof and a Liposomal Platinum Complex |
| 02/28/2008 | US20080050424 Transdermal therapeutic system for treating parkinsonism |
| 02/28/2008 | US20080050421 Methods for reducing neovascularization or edema |
| 02/28/2008 | US20080050420 Methods for reducing neovascularization or edema |
| 02/28/2008 | US20080050415 Polymeric/ceramic composite materials for use in medical devices |
| 02/28/2008 | US20080050414 Methods For Treating Or Preventing Restenosis And Other Vascular Proliferative Disorders |
| 02/28/2008 | US20080050405 Ringworm Vaccine |
| 02/28/2008 | US20080050387 Non-Androgen Dependent Roles for Androgen Receptor and Non-Androgen Related Inhibitors of Androgen Receptor |
| 02/28/2008 | US20080050386 Novel proteins, gene encoding the same and method of utilization thereof |
| 02/28/2008 | US20080050384 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 02/28/2008 | US20080050382 Granulysin and uses thereof |
| 02/28/2008 | US20080050379 Cancer gene determination and therapeutic screening using signature gene sets |
| 02/28/2008 | US20080050378 A ribonucleotide sequence corresponding to a gene KIF11 target sequence, where the antisense strand comprises a ribonucleotide sequence complementary to the sense strand; sense/anntisense strands hybridize to form double-stranded molecule which inhibits cell expression of KIf11 (SEQ ID NO: 34) |
| 02/28/2008 | US20080050375 Modulators to transforming growth factors; for disorders related to proliferation and differentiation, migration, apoptosis, embryonic development, extracellular matrix formation, bone development, wound healing, hematopoiesis, and immune and inflammatory responses |
| 02/28/2008 | US20080050373 Treatment with anti-erbb2 antibodies |
| 02/28/2008 | US20080050368 Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith |
| 02/28/2008 | US20080050364 Treatment of LFA-1 Associated Disorders with Increasing Doses of LFA-1 Antagonist |
| 02/28/2008 | US20080050363 Novel nucleic acid molecules encoding opioid growth factor receptors |
| 02/28/2008 | US20080050362 Methods of Inhibiting Tumor Cell Aggressiveness Using The Microenvironment of Human Embryonic Stem Cells |
| 02/28/2008 | US20080050361 Staphylococcus aureas specific anti-infectives |
| 02/28/2008 | US20080050359 Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
| 02/28/2008 | US20080050358 Identification of Snps Associated with Hyperlipidemia, Dyslipidemia and Defective Carbohydrate Metabolism |
| 02/28/2008 | US20080050353 Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine |
| 02/28/2008 | US20080050342 Genetic inhibition by double-stranded RNA |
| 02/28/2008 | US20080050337 Method for using calcium-sensitive potassium channel agonist for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| 02/28/2008 | US20080050336 Hepatitis C Virus Inhibitors |
| 02/28/2008 | US20080050335 Ophthalmic Solutions |
| 02/28/2008 | US20080050331 Cosmetic Composition Containing A Protease Activator |
| 02/28/2008 | US20080050315 Diagnostics and Therapeutics for Diseases Associated with Protein Kinase, Cgmp-Dependent, Type I (Prkg1) |
| 02/28/2008 | US20080050314 Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b) |
| 02/28/2008 | US20080050311 Monoclonal Antibody hPAM4 |
| 02/28/2008 | US20080050310 Antibodies and immunoconjugates and uses therefor |
| 02/28/2008 | CA2838089A1 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same |
| 02/28/2008 | CA2707204A1 Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic |
| 02/28/2008 | CA2697675A1 Intrathecal administration of triptan compositions to treat non-migraine pain |
| 02/28/2008 | CA2677001A1 4-thio substituted quinoline and naphthyridine compounds |
| 02/28/2008 | CA2675942A1 Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists |
| 02/28/2008 | CA2665804A1 Urea compound or salt thereof |
| 02/28/2008 | CA2663937A1 Suppression of estrus in mares by a single injection method |
| 02/28/2008 | CA2661898A1 Indazole derivatives that inhibit trpv1 and uses thereof |
| 02/28/2008 | CA2661827A1 Therapeutic substituted thiazolidinones, oxazolidinones, and related compounds |
| 02/28/2008 | CA2661765A1 Antisense composition and method for inhibition of mirna biogenesis |
| 02/28/2008 | CA2661618A1 Stabilized pharmaceutical composition |
| 02/28/2008 | CA2661613A1 Controlled release system and method for manufacturing the same |
| 02/28/2008 | CA2661553A1 Method of treating or preventing oxidative stress-related disease |
| 02/28/2008 | CA2661547A1 Solid dosage form |
| 02/28/2008 | CA2661546A1 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same |
| 02/28/2008 | CA2661538A1 Novel macrolides and ketolides having antimicrobial activity |
| 02/28/2008 | CA2661503A1 Inhibitors of 11.beta. -hydroxysteroid dehydrogenase type 1 |
| 02/28/2008 | CA2661496A1 Pharmaceutical combinations for the treatment of respiratory diseases |
| 02/28/2008 | CA2661495A1 Method of reducing neuronal cell damage |
| 02/28/2008 | CA2661486A1 Cationic latex as a carrier for bioactive ingredients and methods for making and using the same |
| 02/28/2008 | CA2661483A1 Pharmacokinetically improved 2-phenyl-substituted imidazotriazinone derivatives and their use |
| 02/28/2008 | CA2661481A1 Powder formulations for inhalation containing enantiomerically pure beta-agonists |
| 02/28/2008 | CA2661462A1 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| 02/28/2008 | CA2661459A1 Di-aromatic substituted amides as inhibitors for glyt1 |
| 02/28/2008 | CA2661442A1 Aerosol formulation for the inhalation of beta-agonists |
| 02/28/2008 | CA2661440A1 Compounds for treating proliferative disorders |
| 02/28/2008 | CA2661437A1 Use of azabicyclo hexane derivatives |
| 02/28/2008 | CA2661436A1 Isoquinoline, quinazoline and phthalazine derivatives |
| 02/28/2008 | CA2661430A1 Long-lasting absorption of flavonoids |
| 02/28/2008 | CA2661422A1 Methods and compositions for treating cancer |
| 02/28/2008 | CA2661333A1 Salt of phenoxypyridine derivative or crystal thereof and process for producing the same |
| 02/28/2008 | CA2661329A1 Anti-diabetes composition containing chicoric acid and/or one of the metabolites thereof |
| 02/28/2008 | CA2661307A1 Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr) |
| 02/28/2008 | CA2661299A1 Matrix metalloproteinase inhibitors |
| 02/28/2008 | CA2661292A1 Compositions and methods for treating myelosuppression |
| 02/28/2008 | CA2661223A1 4-aminoquinazoline derivatives and methods of use thereof |
| 02/28/2008 | CA2661220A1 Multimediator transporter inhibitors for use in treatment of central nervous system disorders |
| 02/28/2008 | CA2661187A1 Piperidine derivatives |
| 02/28/2008 | CA2661166A1 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| 02/28/2008 | CA2661164A1 4-substituted phenoxyphenylacetic acid derivatives |
| 02/28/2008 | CA2661143A1 Enantiomerically pure beta agonists, manufacturing and use thereof |
| 02/28/2008 | CA2661054A1 Prophylactic and/or therapeutic agents for peripheral neuropathy |
| 02/28/2008 | CA2661044A1 Kw-3902 conjugates that do not cross the blood-brain barrier |
| 02/28/2008 | CA2661017A1 Organic compounds |
| 02/28/2008 | CA2660963A1 Aza-benzothiophenyl compounds and methods of use |
| 02/28/2008 | CA2660957A1 2-phenoxy pyrimidinone analogues |
| 02/28/2008 | CA2660951A1 Haloalkyl-substituted pyrimidinone derivatives |
| 02/28/2008 | CA2660741A1 Treatment and prevention of intestinal fibrosis |
| 02/28/2008 | CA2660690A1 Treatment of fibrosing disorders |
| 02/28/2008 | CA2660570A1 Substituted acylanilides and methods of use thereof |
| 02/28/2008 | CA2660546A1 Aza-benzofuranyl compounds and methods of use |
| 02/28/2008 | CA2660531A1 Compounds for treatment of proliferative disorders |
| 02/28/2008 | CA2660524A1 Compounds for treating proliferative disorders |
| 02/28/2008 | CA2660515A1 Synthesis, polymorphs, and pharmaceutical formulation of a faah inhibitor |
| 02/28/2008 | CA2660169A1 Fluorinated ligands for targeting peripheral benzodiazepine receptors |
| 02/28/2008 | CA2660138A1 Galenic formulations of organic compounds |
| 02/28/2008 | CA2660084A1 Biphenyl substituted spirotetronic acids and their use for the treatment of retroviral diseases |
| 02/28/2008 | CA2659991A1 Amides as sphingomyeline inhibitors |
| 02/28/2008 | CA2659952A1 8-hydroxyquinoline compounds and methods thereof |
| 02/28/2008 | CA2659914A1 Antioxidant for preventing and treating diseases caused by oxidative stress |
| 02/28/2008 | CA2659851A1 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors |
| 02/28/2008 | CA2659464A1 Rnai-mediated inhibition of gremlin for treatment of iop-related conditions |